



Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting

October 14, 2024

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- [Biora Therapeutics, Inc.](#) (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on the company's 00-size BioJet™ device at the [14th Annual Partnership Opportunities in Drug Delivery \(PODD\) meeting](#), taking place in Boston, October 28–29, 2024.

"As part of the development of our clinical-ready BioJet device, we were able to reduce its size from 000 to 00, while slightly increasing the payload capacity," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "Market research indicates a strong patient preference for a 00-size device, a preference that is shared by our pharma collaborators. We are excited about the progress we've made with this revolutionary, needleless, liquid injection technology in a smaller capsule that is readily accepted by patients. In addition to providing updates on our BioJet and NaviCap platforms, the PODD meeting also provides an opportunity to meet with a number of our existing pharma collaborators as we are in the process of expanding those relationships."

Details of the presentation are as follows:

Presentation Title: Solving Drug Delivery Challenges with Ingestible Drug-Device Combinations
Date & Time: October 28, 2024, 3:30 – 3:45 PM Eastern Time
Track: 3A: Oral, Mucosal, Transdermal & Other Non-Injectable Technologies
Location: Westin Boston Seaport, Grand Ballroom D/E, Concourse Level

PODD brings together professionals from pharma, biotech, and drug delivery industries to assess delivery needs and share information on the latest advances in drug delivery technologies that can potentially improve the delivery of various types of drugs, including proteins, peptides, mRNA therapies, oncology therapeutics, and small molecules.

About Biora Therapeutics

Biora Therapeutics is a clinical-stage biotech company developing two smart pill-based therapeutics platforms: the [NaviCap™ platform for colon-targeted treatment of IBD](#) designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the [Bio-Jet™ platform for oral delivery of large molecules](#) designed to replace injection with needle-free delivery.

For more information, visit [bioratherapeutics.com](#) or follow the company on [LinkedIn](#) or [X](#).

Safe Harbor Statement or Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model-based data projections for the BT-600 program, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "envision," "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "anticipate," "forward," "believe," "design," "estimate," "predict," "projects," "projecting," "potential," "plan," "goal(s)," "target," or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact

Chuck Padala
Managing Director, LifeSci Advisors
JR@bioratherapeutics.com
(646) 627-8390

Media Contact

Liz Robinson
CG Life
lrobinson@cglife.com